Abstract: The disclosure describes a distributed, pluggable architecture for an artificial reality (AR) system that enables concurrent execution and collaborative scene rendering for multiple artificial reality applications. For example, an AR system includes an image capture device configured to capture image data representative of a physical environment. The AR system also includes a head-mounted display (HMD) configured to output artificial reality content. The AR system further includes a plurality of concurrently executing artificial reality client applications. The AR system also includes a concurrent application engine configured to control rendering the artificial reality content as a common scene that include one or more objects from each of the plurality of artificial reality applications.

Abstract: Embodiments of this invention include methods for detecting in vitro the presence of Memory B cells in peripheral blood mononuclear cells (PBMCs) that produce antibodies reactive to CNS antigens associated with Multiple Sclerosis (MS). Stimulating PBMCs from patients with MS by a polyclonal stimulating agent promotes the ability of B-lymphocytes, when exposed to a CNS antigen, to produce antibodies specific for the CNS antigen. In contrast, stimulating PBMCs from subjects without MS do not produce such responses.

Abstract: Embodiments of this invention include image-based systems and methods for detection of one or more analytes. A surface has identifiable analyte-specific capture particle(s) immobilised thereto at any point of an assay, to which different analytes attach due to the affinity of analyte-specific capture molecule(s) linked to the surface of the capture particle(s) for the analyte. Analyte-specific detector molecules with conjugated detection moieties are then attached to the analyte, and a computer assisted, image-based detection system captures images of the capture particles with or without attached analytes and detector molecules. By using different subsets of analyte-specific capture molecules, each subset having a characteristic identifiable feature; it is now possible to perform capture particle-based, rapid multiplex assays of biological and non-biological analytes without flow.

Abstract: Embodiments of the present invention relate to devices and methods for detecting opsonophagocytotic antibodies using detection particles having product-specific detection reagents and having a characteristic spectral feature. Detection substrates, include microwells. Phagocytic cells are grown in the microwells, and a sample of serum or other bodily fluid from a patient is introduced into the wells, along with a set of detection particles, each set having an antigen recognized by opsonophagocytotic antibodies. The detection particles bind to the antibodies present in the sample and the phagocytic cells then take up the detection particles, labeling the phagocytic cells. The cells are then visualized via image analysis, thereby detecting the presence of, and the types of the opsonophagocytotic antibodies in the sample.

Abstract: Embodiments of this invention include methods for detecting in vitro the presence in peripheral blood mononuclear cells (PBMCs), and in serum or plasma, of antibodies reactive to and of lymphocytes that are responsive to CNS antigens associated with Multiple Sclerosis (MS). These CNS antigens include, but are not limited to whole brain lysate and the myelin antigens myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), MOG peptides (MOGps), proteolipid protein (PLP), and PLP peptides (PLPps). Stimulating PBMCs from patients with MS by CNS antigens cause B-lymphocytes to produce antibodies specific for CNS antigen, and causes T-lymphocytes to produce T-lymphocyte-specific cytokines, including interferon gamma (IFN-y), interleukin-2 (IL-2), or interleukin-17 (IL-17). In contrast, stimulating PBMCs from subjects without MS do not produce such responses.

Abstract: Embodiments of this invention include image-based systems and methods for detection of one or more analytes. A surface has identifiable analyte-specific capture particle(s) immobilised thereto at any point of an assay, to which different analytes attach due to the affinity of analyte-specific capture molecule(s) linked to the surface of the capture particle(s) for the analyte. Analyte-specific detector molecules with conjugated detection moieties are then attached to the analyte, and a computer assisted, image-based detection system captures images of the capture particles with or without attached analytes and detector molecules. By using different subsets of analyte-specific capture molecules, each subset having a characteristic identifiable feature; it is now possible to perform capture particle-based, rapid multiplex assays of biological and non-biological analytes without flow.

Abstract: Embodiments of the present invention relate to devices and methods for detecting opsonophagocytotic antibodies using detection particles having product-specific detection reagents and having a characteristic spectral feature. Detection substrates, include microwells. Phagocytic cells are grown in the microwells, and a sample of serum or other bodily fluid from a patient is introduced into the wells, along with a set of detection particles, each set having an antigen recognized by opsonophagocytotic antibodies. The detection particles bind to the antibodies present in the sample and the phagocytic cells then take up the detection particles, labeling the phagocytic cells. The cells are then visualized via image analysis, thereby detecting the presence of, and the types of the opsonophagocytotic antibodies in the sample.

Abstract: The invention concerns a method for detecting disorders of iron metabolism and in particular the differential diagnosis of disorders of iron metabolism by means of three independent parameters. The differential diagnosis can be used to classify disorders of iron metabolism and to recommend the required treatment and to monitor the progress and response to treatment.

Abstract: The invention concerns a method for detecting disorders of iron metabolism and in particular the differential diagnosis of disorders of iron metabolism by means of three independent parameters. The differential diagnosis can be used to classify disorders of iron metabolism and to recommend the required treatment and to monitor the progress and response to treatment.

Abstract: The present invention relates to the use of erythropoietin for the treatment of disturbances of iron distribution in heart diseases.

Abstract: A method of, and pharmaceutical composition for, treating disturbances of iron distribution in diabetes using erythropoietin are disclosed.

Abstract: The present invention relates to the use of erythropoietin for the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases.

Abstract: The present invention concerns the use of hepcidin as a marker for detecting inflammatory chronic diseases and especially for a differential diagnosis to detect inflammatory chronic diseases and/or non-inflammatory chronic diseases. The present invention also concerns a method for detecting inflammatory chronic diseases, non-inflammatory chronic diseases and/or acute phase reactions comprising the determination of hepcidin.

Abstract: Embodiments include systems and methods for summoning help and locating a person, comprising transmitting information over a wireless network in response to a user action; wherein the information includes the geographic location of the user.

Abstract: The invention concerns a method for determining vitamin B12, B6 or/and folic acid disorders and in particular the differential diagnosis of vitamin B12, vitamin B6 or/and folic acid disorders by means of three or four independent parameters. The differential diagnosis can be used to detect a vitamin B12, vitamin B6 or/and folic acid disorder and to recommend the required treatment and to monitor the course and success of treatment.

Abstract: Embodiments of the present invention relate to devices and methods for detecting cellular products using detection particles having product-specific detection reagents and having a characteristic spectral feature. In particular, devices and methods are provided for measuring secreted cellular products including cytokines. Detection substrates, include microwells having product-specific capture reagents thereon or comprising hydrophobic membranes are described having greater capability to detect products from individual cells in a mixture of heterogeneous cells. With the use of multiple detection particles, multiple cellular products can be detected in a single well. Additionally, using the inherent spectral properties of detection particles, no enzymatic reactions are needed to visualize a secreted product, thereby increasing the sensitivity, reproducibility and ease of use.

Abstract: A kit comprising an erythropoietin and a modified hemoglobin is disclosed.

Abstract: The present invention relates to the use of erythropoietin for the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases.

Abstract: The present invention concerns the use of hepcidin as a marker for detecting inflammatory chronic diseases and especially for a differential diagnosis to detect inflammatory chronic diseases and/or non-inflammatory chronic diseases. The present invention also concerns a method for detecting inflammatory chronic diseases, non-inflammatory chronic diseases and/or acute phase reactions comprising the determination of hepcidin.

Abstract: The invention concerns a method for detecting coronary syndromes, in particular, coronary artery disease (CAD), using risk markers.